There still could have been questions pointed dire
Post# of 36537
(Total Views: 212)
Posted On: 08/27/2020 9:10:02 AM
There still could have been questions pointed directly at NGIO as well.
Have all SEC questions been addressed now?
What would be the expectations of when the S-1 would be put in? Yes, we know that the SEC is reviewing the Form 10, but because of previous questions, what is the expectation for the S-1 for NGIO with all the delays that have happened due to SEC questions.
Can NGIO management delve more into what is going on with the Peptides research?
Can NGIO management delve into more of the current deals?
This could all be explained more on the NGIO call as it pertains directly to NGIO.
Just my viewpoint.
Have all SEC questions been addressed now?
What would be the expectations of when the S-1 would be put in? Yes, we know that the SEC is reviewing the Form 10, but because of previous questions, what is the expectation for the S-1 for NGIO with all the delays that have happened due to SEC questions.
Can NGIO management delve more into what is going on with the Peptides research?
Can NGIO management delve into more of the current deals?
This could all be explained more on the NGIO call as it pertains directly to NGIO.
Just my viewpoint.
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼